Bumper Offer - Urjas oil Just @ Rs. 1
CA 007 125/500 Injection 5 Ml is a prescription drug, available for use as Injection. CA 007 125/500 Injection 5 Ml also has some secondary and off-label uses. These are listed below.
The right dosage of CA 007 125/500 Injection 5 Ml depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Apart from the aforementioned side effects, CA 007 125/500 Injection 5 Ml can also lead to other problems, which have been listed below. These side effects of CA 007 125/500 Injection 5 Ml are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of CA 007 125/500 Injection 5 Ml is Safe for pregnant women and Mild for women who are breastfeeding. Warnings related to CA 007 125/500 Injection 5 Ml's effects on the liver, heart and kidney, if any, have been listed below.
CA 007 125/500 Injection 5 Ml is not recommended if you suffer from certain medical conditions as it can have adverse effects. Dehydration, Parkinson's Disease, Hearing Loss are examples of such conditions. Other conditions have been mentioned below in the CA 007 125/500 Injection 5 Ml contraindications section.
Besides this, CA 007 125/500 Injection 5 Ml may also have severe interaction with some medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking CA 007 125/500 Injection 5 Ml is considered not safe while driving, and is not addictive.
CA 007 125/500 Injection 5 Ml is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when CA 007 125/500 Injection 5 Ml is used -
Moderate
Mild
Unknown
Is the use of CA 007 125/500 Injection 5 Ml safe for pregnant women?
Pregnant women can take CA 007 without worrying about any side effects.
Is the use of CA 007 125/500 Injection 5 Ml safe during breastfeeding?
Side effects of CA 007 for breastfeeding are little to none, so you can take it without doctor's advice.
What is the effect of CA 007 125/500 Injection 5 Ml on the Kidneys?
CA 007 rarely affects the kidneys.
What is the effect of CA 007 125/500 Injection 5 Ml on the Liver?
Using CA 007 does not have any harmful effects on the liver.
What is the effect of CA 007 125/500 Injection 5 Ml on the Heart?
Using CA 007 does not have any harmful effects on the heart.
CA 007 125/500 Injection 5 Ml should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take CA 007 125/500 Injection 5 Ml unless your doctor advises you to do so -
Is this CA 007 125/500 Injection 5 Ml habit forming or addictive?
No, you will not get addicted to CA 007 125/500 Injection 5 Ml.
Interaction between Food and CA 007 125/500 Injection 5 Ml
Taking CA 007 125/500 Injection 5 Ml with food does not harm your health.
Interaction between Alcohol and CA 007 125/500 Injection 5 Ml
It is difficult to say anything about the effect of CA 007 125/500 Injection 5 Ml and alcohol. No research has been done on this yet.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Arikayce (amikacin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 749
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 136-137
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 291-292
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 729
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Maxipime™ (Cefepime Hydrochloride)